[HTML][HTML] Impact of EGFR mutation status on tumor response and progression free survival after first-line chemotherapy in patients with advanced non-small-cell lung …
Objectives Non-small-cell lung cancer (NSCLC) patients harboring sensitive epidermal
growth factor receptor (EGFR) mutations derive greater benefits from EGFR-tyrosine kinase …
growth factor receptor (EGFR) mutations derive greater benefits from EGFR-tyrosine kinase …
[PDF][PDF] Impact of EGFR mutation status on tumor response and progression free survival after first-line chemotherapy in patients with advanced non-small-cell lung …
W Liang, Y Zhang, S Kang, H Pan, W Shao, Q Deng… - 2014 - researchgate.net
Objectives: Non-small-cell lung cancer (NSCLC) patients harboring sensitive epidermal
growth factor receptor (EGFR) mutations derive greater benefits from EGFR-tyrosine kinase …
growth factor receptor (EGFR) mutations derive greater benefits from EGFR-tyrosine kinase …
Impact of EGFR mutation status on tumor response and progression free survival after first-line chemotherapy in patients with advanced non-small-cell lung cancer: a …
W Liang, Y Zhang, S Kang, H Pan… - Journal of Thoracic …, 2014 - jtd.amegroups.org
Objectives: Non-small-cell lung cancer (NSCLC) patients harboring sensitive epidermal
growth factor receptor (EGFR) mutations derive greater benefits from EGFR-tyrosine kinase …
growth factor receptor (EGFR) mutations derive greater benefits from EGFR-tyrosine kinase …
[PDF][PDF] Impact of EGFR mutation status on tumor response and progression free survival after first-line chemotherapy in patients with advanced non-small-cell lung …
W Liang, Y Zhang, S Kang, H Pan, W Shao, Q Deng… - 2014 - cdn.amegroups.cn
Objectives: Non-small-cell lung cancer (NSCLC) patients harboring sensitive epidermal
growth factor receptor (EGFR) mutations derive greater benefits from EGFR-tyrosine kinase …
growth factor receptor (EGFR) mutations derive greater benefits from EGFR-tyrosine kinase …
[PDF][PDF] Impact of EGFR mutation status on tumor response and progression free survival after first-line chemotherapy in patients with advanced non-small-cell lung …
W Liang, Y Zhang, S Kang, H Pan, W Shao, Q Deng… - 2014 - academia.edu
Objectives: Non-small-cell lung cancer (NSCLC) patients harboring sensitive epidermal
growth factor receptor (EGFR) mutations derive greater beneits from EGFR-tyrosine kinase …
growth factor receptor (EGFR) mutations derive greater beneits from EGFR-tyrosine kinase …
Impact of EGFR mutation status on tumor response and progression free survival after first-line chemotherapy in patients with advanced non-small-cell lung cancer: a …
W Liang, Y Zhang, S Kang, H Pan… - Journal of thoracic …, 2014 - pubmed.ncbi.nlm.nih.gov
Objectives Non-small-cell lung cancer (NSCLC) patients harboring sensitive epidermal
growth factor receptor (EGFR) mutations derive greater benefits from EGFR-tyrosine kinase …
growth factor receptor (EGFR) mutations derive greater benefits from EGFR-tyrosine kinase …
Impact of EGFR mutation status on tumor response and progression free survival after first-line chemotherapy in patients with advanced non-small-cell lung cancer: a …
W Liang, Y Zhang, S Kang, H Pan, W Shao… - Journal of Thoracic …, 2014 - europepmc.org
Objectives Non-small-cell lung cancer (NSCLC) patients harboring sensitive epidermal
growth factor receptor (EGFR) mutations derive greater benefits from EGFR-tyrosine kinase …
growth factor receptor (EGFR) mutations derive greater benefits from EGFR-tyrosine kinase …
[PDF][PDF] Impact of EGFR mutation status on tumor response and progression free survival after first-line chemotherapy in patients with advanced non-small-cell lung …
W Liang, Y Zhang, S Kang, H Pan… - JOURNAL of …, 2014 - cdn.amegroups.cn
Objectives: Non-small-cell lung cancer (NSCLC) patients harboring sensitive epidermal
growth factor receptor (EGFR) mutations derive greater benefits from EGFR-tyrosine kinase …
growth factor receptor (EGFR) mutations derive greater benefits from EGFR-tyrosine kinase …
[HTML][HTML] Impact of EGFR mutation status on tumor response and progression free survival after first-line chemotherapy in patients with advanced non-small-cell lung …
W Liang, Y Zhang, S Kang, H Pan… - Journal of Thoracic …, 2014 - jtd.amegroups.org
Objectives: Non-small-cell lung cancer (NSCLC) patients harboring sensitive epidermal
growth factor receptor (EGFR) mutations derive greater benefits from EGFR-tyrosine kinase …
growth factor receptor (EGFR) mutations derive greater benefits from EGFR-tyrosine kinase …